(Q47984250)

7 February 2018

title

FGFR3 mutations in prostate cancer: association with low-grade tumors. (English)

1 reference

7 February 2018

1 reference

Silvia Hernández

1

1 reference

7 February 2018

Silvia de Muga

2

1 reference

7 February 2018

Laia Agell

3

1 reference

7 February 2018

Nuria Juanpere

4

1 reference

7 February 2018

Raquel Esgueva

5

1 reference

7 February 2018

José A Lorente

6

1 reference

7 February 2018

Sergi Mojal

7

1 reference

7 February 2018

Sergio Serrano

8

1 reference

7 February 2018

Josep Lloreta

9

1 reference

7 February 2018

publication date

17 April 2009

1 reference

7 February 2018

published in

Modern Pathology

1 reference

7 February 2018

volume

22

1 reference

7 February 2018

page(s)

848-856

1 reference

7 February 2018

issue

6

1 reference

7 February 2018

https://scigraph.springernature.com/pub.10.1038/modpathol.2009.46

exact match

0 references

cites work

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.46

Screening for prostate cancer with prostate-specific antigen. An examination of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.46

Role of androgens and fibroblast growth factors in prostatic development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.46

Fibroblast growth factor receptor 2 tyrosine kinase is required for prostatic morphogenesis and the acquisition of strict androgen dependency for adult tissue homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.46

Fibroblast growth factor receptor signaling through MEK-ERK is required for prostate bud induction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.46

Directionally specific paracrine communication mediated by epithelial FGF9 to stromal FGFR3 in two-compartment premalignant prostate tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.46

Fibroblast growth factor 17 is over-expressed in human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.46

Fibroblast growth factors, their receptors and signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.46

Conditional activation of FGFR1 in the prostate epithelium induces angiogenesis with concomitant differential regulation of Ang-1 and Ang-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.46

Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.46

Concomitant down-regulation of SPRY1 and SPRY2 in prostate carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.46

The expression of Sprouty1, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.46

Epigenetic inactivation of the human sprouty2 (hSPRY2) homologue in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.46

Fibroblast growth factor receptor 3 mutations in achondroplasia and related forms of dwarfism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.46

FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.46

FGF signaling in the developing endochondral skeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.46

Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.46

Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.46

Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.46

Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.46

Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.46

FGFR3 mutations in benign skin tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.46

Fibroblast growth factor receptor 3 mutations in epidermal nevi and associated low grade bladder tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.46

Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.46

Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.46

Molecular markers for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.46

Genomics of prostate cancer: is there anything to "translate"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.46

FGFR3 mutations in epidermal nevi and seborrheic keratoses: lessons from urothelium and skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.46

Somatic oncogenic mutations, benign skin lesions and cancer progression: where to look next?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.46

Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.46

Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.46

High frequency of FGFR3 mutations in adenoid seborrheic keratoses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.46

Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.46

FGFR3 dimer stabilization due to a single amino acid pathogenic mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.46

FGFR3 and Tp53 Mutations in T1G3 Transitional Bladder Carcinomas: Independent Distribution and Lack of Association with Prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.46

Increased expression of FGF-8 isoforms and FGF receptors in human premalignant prostatic intraepithelial neoplasia lesions and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.46

7 January 2021

Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.46

7 January 2021

No evidence for fibroblast growth factor receptor 3 (FGFR-3) R248C/S249C mutations in human prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.46

7 January 2021

FGFR3 mutations in seborrheic keratoses are already present in flat lesions and associated with age and localization

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.46

7 January 2021

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.46

1 reference

7 January 2021

10.1038/MODPATHOL.2009.46

Identifiers

DOI

1 reference

7 February 2018

Dimensions Publication ID

1022896827

0 references

Fatcat ID

release_hwlexiss5jazfmfozo7tp2o3wq

0 references

PubMed ID

19377444

1 reference

7 February 2018